



COPY OF PAPERS  
ORIGINALLY FILED

#4A  
Bp  
6-11-02

S/N 10/027,038

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stephen Quirk

Examiner: Unknown

Serial No.: 10/027,038

Group Art Unit: 1646

Filed: December 20, 2001

Docket: 1443.026US1

Title: MODULAR PEPTIDE-BASED REAGENT

**RECEIVED**

PRELIMINARY AMENDMENT

APR 24 2002

Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", mailed February 12, 2002, please amend the above-identified patent application as follows:

In the Specification

Please enter the enclosed SEQUENCE LISTING into the specification.

Please make the paragraph substitutions indicated in the appendix entitled Clean Version of Amended Specification Paragraphs. The specific changes incorporated in the substitute paragraphs are shown in the following marked-up versions of the original paragraphs:

Please amend the paragraph beginning at line 7, page 5 of the specification as follows:

A1  
Figure 1 provides a DNA (SEQ ID NO:12) and amino acid (SEQ ID NO:11) sequence of the SAP peptide. The asterisk denotes the stop codon. The codon selection is biased towards *E. coli*. The initial methionine is used if the SAP molecule is to be produced using recombinant methodology. If the peptide molecule is to be produced chemically, then the methionine residue can be omitted.

Please amend the paragraph beginning at line 12, page 5 of the specification as follows:

A2  
Figure 2 provides the final SAP DNA sequence (SEQ ID NO:13). Flanking nucleotides were added to the DNA sequence shown in Figure 1 to facilitate cloning. A 5' Nde I site is underlined, as are the 3' Bam HI and internal Sma I sites.